Literature DB >> 2041257

[Analysis of dysanapsis in healthy twins and sons of patients with chronic obstructive lung disease].

M Nishimura1, T Kusaka, S Kobayashi, M Yamamoto, Y Akiyama, Y Kawakami.   

Abstract

Pulmonary function tests and tracheal cross-sectional area (X-SA) measured on chest roentgenograms were analyzed in 72 healthy pairs of twins and in 34 healthy sons of patients with chronic obstructive lung disease. In the twin study, genetic influence was positive on most pulmonary function tests, including VC, FEV1/FVC, V25, but not so on X-SA. The ratio of X-SA to VC, which represents dysanapsis, had no relation to sex nor height. However, the ratio of X-SA/VC showed marked sex-associated differences, when expressed as a function of VC, and had a negative correlation with VC both in men and women. The ratio of X-SA/VC was significantly lower in sons of patients with COPD than in normal controls, which was caused by significantly larger VC in the former group. The relatively low ratio of tracheal size to lung size may partly explain the susceptibility to the possible future development of COPD in those subjects.

Entities:  

Mesh:

Year:  1991        PMID: 2041257

Source DB:  PubMed          Journal:  Nihon Kyobu Shikkan Gakkai Zasshi        ISSN: 0301-1542


  3 in total

1.  Familial aggregation of FEF(25-75) and FEF(25-75)/FVC in families with severe, early onset COPD.

Authors:  D L DeMeo; V J Carey; H A Chapman; J J Reilly; L C Ginns; F E Speizer; S T Weiss; E K Silverman
Journal:  Thorax       Date:  2004-05       Impact factor: 9.139

Review 2.  Computed Tomographic Airway Morphology in Chronic Obstructive Pulmonary Disease. Remodeling or Innate Anatomy?

Authors:  Alejandro A Diaz; Raul San José Estépar; George R Washko
Journal:  Ann Am Thorac Soc       Date:  2016-01

3.  Practical surrogate marker of pulmonary dysanapsis by simple spirometry: an observational case-control study in primary care.

Authors:  Satomi Shiota; Masako Ichikawa; Kazuhiro Suzuki; Yoshinosuke Fukuchi; Kazuhisa Takahashi
Journal:  BMC Fam Pract       Date:  2015-03-26       Impact factor: 2.497

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.